Loading…

Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)

Widow spider envenomation may cause an array of clinical effects, the hallmark of which is intense pain. Often, response to treatment must be judged by perceived changes in pain intensity due to lack of a reliable set of abnormal clinical findings. This study was conducted to quantify pain intensity...

Full description

Saved in:
Bibliographic Details
Published in:Clinical toxicology (Philadelphia, Pa.) Pa.), 2005-10, Vol.43 (6), p.707-708
Main Authors: Gonzales, V A, Vazquez, I M, Robles, G D, Stanford, C F, Bogdan, G M, Garcia-Ubbelohde, W
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 708
container_issue 6
container_start_page 707
container_title Clinical toxicology (Philadelphia, Pa.)
container_volume 43
creator Gonzales, V A
Vazquez, I M
Robles, G D
Stanford, C F
Bogdan, G M
Garcia-Ubbelohde, W
description Widow spider envenomation may cause an array of clinical effects, the hallmark of which is intense pain. Often, response to treatment must be judged by perceived changes in pain intensity due to lack of a reliable set of abnormal clinical findings. This study was conducted to quantify pain intensity in patients with latrodectism using the VAS. As part of a clinical trial, adult patients diagnosed with latrodectism and not treated with analgesics received a 5 to 10-min infusion of investigational Latrodectus antivenom (AV). If sufficient clinical improvement was not achieved, additional doses were infused at 30 and 60 min. Patients completed a VAS for pain before AV (0 min), at the end of Dose 1 (30 min), and at the end of observation (240 min). VAS score was the distance along a 10 cm line to the patient's mark with left side = "no pain" and right side = "worst possible pain". Vital signs (SBP, DBP, HR, RR) were also measured. VAS scores and vital signs were compared across time using RM ANOVAs (p22, 48%), generalized diaphoresis (48%), nausea/vomiting (29%), and tachycardia (HR greater than or equal to 100, 19%). At the end of Dose 1, there were significant decreases in mean VAS (3.3 plus or minus 2.3 cm = mild pain, p
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_17657520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17657520</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_176575203</originalsourceid><addsrcrecordid>eNqNirsOgkAQAK_QRHz8w1ZGCxIQD9TOGI2NlY_WbHCFNceB7KHx76XwA6xmMpmO8kKtYz-KddBTfZFHEESL-TL01PlAKE3NNoMK2QJbR1bYfVpri2OyTuDNLgeDri5vlDqWYgWnnODF0qABtGjKDCRFQzC5rI_Toere0QiNfhyo8W572uz9qi6fDYm7FiwpGYOWykauYRLrRM-C6O_xCwaYQyI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17657520</pqid></control><display><type>article</type><title>Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Gonzales, V A ; Vazquez, I M ; Robles, G D ; Stanford, C F ; Bogdan, G M ; Garcia-Ubbelohde, W</creator><creatorcontrib>Gonzales, V A ; Vazquez, I M ; Robles, G D ; Stanford, C F ; Bogdan, G M ; Garcia-Ubbelohde, W</creatorcontrib><description>Widow spider envenomation may cause an array of clinical effects, the hallmark of which is intense pain. Often, response to treatment must be judged by perceived changes in pain intensity due to lack of a reliable set of abnormal clinical findings. This study was conducted to quantify pain intensity in patients with latrodectism using the VAS. As part of a clinical trial, adult patients diagnosed with latrodectism and not treated with analgesics received a 5 to 10-min infusion of investigational Latrodectus antivenom (AV). If sufficient clinical improvement was not achieved, additional doses were infused at 30 and 60 min. Patients completed a VAS for pain before AV (0 min), at the end of Dose 1 (30 min), and at the end of observation (240 min). VAS score was the distance along a 10 cm line to the patient's mark with left side = "no pain" and right side = "worst possible pain". Vital signs (SBP, DBP, HR, RR) were also measured. VAS scores and vital signs were compared across time using RM ANOVAs (p&lt;.01). Twenty-one patients were treated with AV; 11 received only Dose 1. Before AV, mean VAS was 8.2 plus or minus 2.1 cm (severe pain). One or more abnormal signs were present in 18 patients; the other 3 had only minor or moderate pain (VAS = 2-6). Abnormal signs included hypertension (SBP greater than or equal to 130 or DBP greater than or equal to 90, 71%), elevated RR (&gt;22, 48%), generalized diaphoresis (48%), nausea/vomiting (29%), and tachycardia (HR greater than or equal to 100, 19%). At the end of Dose 1, there were significant decreases in mean VAS (3.3 plus or minus 2.3 cm = mild pain, p&lt;.001) and means for all vital signs (p&lt;.001). Abnormal signs resolved in 10 patients (56%). By 240 min, all signs were normal and VAS scores were zero in all but one patient (VAS = 1). Decreases in VAS pain scores during therapy were dramatic and concurrent with normalization of clinical signs. VAS offers quantitative assessment of pain intensity in patients with latrodectism and is effective for evaluating response to therapy, particularly in absence of abnormal signs.</description><identifier>ISSN: 1556-3650</identifier><language>eng</language><ispartof>Clinical toxicology (Philadelphia, Pa.), 2005-10, Vol.43 (6), p.707-708</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Gonzales, V A</creatorcontrib><creatorcontrib>Vazquez, I M</creatorcontrib><creatorcontrib>Robles, G D</creatorcontrib><creatorcontrib>Stanford, C F</creatorcontrib><creatorcontrib>Bogdan, G M</creatorcontrib><creatorcontrib>Garcia-Ubbelohde, W</creatorcontrib><title>Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)</title><title>Clinical toxicology (Philadelphia, Pa.)</title><description>Widow spider envenomation may cause an array of clinical effects, the hallmark of which is intense pain. Often, response to treatment must be judged by perceived changes in pain intensity due to lack of a reliable set of abnormal clinical findings. This study was conducted to quantify pain intensity in patients with latrodectism using the VAS. As part of a clinical trial, adult patients diagnosed with latrodectism and not treated with analgesics received a 5 to 10-min infusion of investigational Latrodectus antivenom (AV). If sufficient clinical improvement was not achieved, additional doses were infused at 30 and 60 min. Patients completed a VAS for pain before AV (0 min), at the end of Dose 1 (30 min), and at the end of observation (240 min). VAS score was the distance along a 10 cm line to the patient's mark with left side = "no pain" and right side = "worst possible pain". Vital signs (SBP, DBP, HR, RR) were also measured. VAS scores and vital signs were compared across time using RM ANOVAs (p&lt;.01). Twenty-one patients were treated with AV; 11 received only Dose 1. Before AV, mean VAS was 8.2 plus or minus 2.1 cm (severe pain). One or more abnormal signs were present in 18 patients; the other 3 had only minor or moderate pain (VAS = 2-6). Abnormal signs included hypertension (SBP greater than or equal to 130 or DBP greater than or equal to 90, 71%), elevated RR (&gt;22, 48%), generalized diaphoresis (48%), nausea/vomiting (29%), and tachycardia (HR greater than or equal to 100, 19%). At the end of Dose 1, there were significant decreases in mean VAS (3.3 plus or minus 2.3 cm = mild pain, p&lt;.001) and means for all vital signs (p&lt;.001). Abnormal signs resolved in 10 patients (56%). By 240 min, all signs were normal and VAS scores were zero in all but one patient (VAS = 1). Decreases in VAS pain scores during therapy were dramatic and concurrent with normalization of clinical signs. VAS offers quantitative assessment of pain intensity in patients with latrodectism and is effective for evaluating response to therapy, particularly in absence of abnormal signs.</description><issn>1556-3650</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNirsOgkAQAK_QRHz8w1ZGCxIQD9TOGI2NlY_WbHCFNceB7KHx76XwA6xmMpmO8kKtYz-KddBTfZFHEESL-TL01PlAKE3NNoMK2QJbR1bYfVpri2OyTuDNLgeDri5vlDqWYgWnnODF0qABtGjKDCRFQzC5rI_Toere0QiNfhyo8W572uz9qi6fDYm7FiwpGYOWykauYRLrRM-C6O_xCwaYQyI</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Gonzales, V A</creator><creator>Vazquez, I M</creator><creator>Robles, G D</creator><creator>Stanford, C F</creator><creator>Bogdan, G M</creator><creator>Garcia-Ubbelohde, W</creator><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20051001</creationdate><title>Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)</title><author>Gonzales, V A ; Vazquez, I M ; Robles, G D ; Stanford, C F ; Bogdan, G M ; Garcia-Ubbelohde, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_176575203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzales, V A</creatorcontrib><creatorcontrib>Vazquez, I M</creatorcontrib><creatorcontrib>Robles, G D</creatorcontrib><creatorcontrib>Stanford, C F</creatorcontrib><creatorcontrib>Bogdan, G M</creatorcontrib><creatorcontrib>Garcia-Ubbelohde, W</creatorcontrib><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical toxicology (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzales, V A</au><au>Vazquez, I M</au><au>Robles, G D</au><au>Stanford, C F</au><au>Bogdan, G M</au><au>Garcia-Ubbelohde, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)</atitle><jtitle>Clinical toxicology (Philadelphia, Pa.)</jtitle><date>2005-10-01</date><risdate>2005</risdate><volume>43</volume><issue>6</issue><spage>707</spage><epage>708</epage><pages>707-708</pages><issn>1556-3650</issn><abstract>Widow spider envenomation may cause an array of clinical effects, the hallmark of which is intense pain. Often, response to treatment must be judged by perceived changes in pain intensity due to lack of a reliable set of abnormal clinical findings. This study was conducted to quantify pain intensity in patients with latrodectism using the VAS. As part of a clinical trial, adult patients diagnosed with latrodectism and not treated with analgesics received a 5 to 10-min infusion of investigational Latrodectus antivenom (AV). If sufficient clinical improvement was not achieved, additional doses were infused at 30 and 60 min. Patients completed a VAS for pain before AV (0 min), at the end of Dose 1 (30 min), and at the end of observation (240 min). VAS score was the distance along a 10 cm line to the patient's mark with left side = "no pain" and right side = "worst possible pain". Vital signs (SBP, DBP, HR, RR) were also measured. VAS scores and vital signs were compared across time using RM ANOVAs (p&lt;.01). Twenty-one patients were treated with AV; 11 received only Dose 1. Before AV, mean VAS was 8.2 plus or minus 2.1 cm (severe pain). One or more abnormal signs were present in 18 patients; the other 3 had only minor or moderate pain (VAS = 2-6). Abnormal signs included hypertension (SBP greater than or equal to 130 or DBP greater than or equal to 90, 71%), elevated RR (&gt;22, 48%), generalized diaphoresis (48%), nausea/vomiting (29%), and tachycardia (HR greater than or equal to 100, 19%). At the end of Dose 1, there were significant decreases in mean VAS (3.3 plus or minus 2.3 cm = mild pain, p&lt;.001) and means for all vital signs (p&lt;.001). Abnormal signs resolved in 10 patients (56%). By 240 min, all signs were normal and VAS scores were zero in all but one patient (VAS = 1). Decreases in VAS pain scores during therapy were dramatic and concurrent with normalization of clinical signs. VAS offers quantitative assessment of pain intensity in patients with latrodectism and is effective for evaluating response to therapy, particularly in absence of abnormal signs.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 1556-3650
ispartof Clinical toxicology (Philadelphia, Pa.), 2005-10, Vol.43 (6), p.707-708
issn 1556-3650
language eng
recordid cdi_proquest_miscellaneous_17657520
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
title Measuring pain intensity in patients with latrodectism: The visual analog scale (VAS)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A45%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measuring%20pain%20intensity%20in%20patients%20with%20latrodectism:%20The%20visual%20analog%20scale%20(VAS)&rft.jtitle=Clinical%20toxicology%20(Philadelphia,%20Pa.)&rft.au=Gonzales,%20V%20A&rft.date=2005-10-01&rft.volume=43&rft.issue=6&rft.spage=707&rft.epage=708&rft.pages=707-708&rft.issn=1556-3650&rft_id=info:doi/&rft_dat=%3Cproquest%3E17657520%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_176575203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17657520&rft_id=info:pmid/&rfr_iscdi=true